Option chain shows key data for Innate Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Innate Pharma.

Innate Pharma (OTC:IPHYF) Stock, Option Chain

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Biotech

News

Penny Stocks

Health Care

General

IPHA

IPHYF

Innate Pharma To Stop COVID-19 Trial With Avdoralimab After Mid-Stage Study Disappoints

Innate Pharma&#39;s Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides Patients

Small Cap

Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients

Innate Pharma SA

Innate Pharma

Comments

Innate Pharma

Innate Pharma (IPHYF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga